BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 12654284)

  • 1. The use of cyclin-dependent kinase inhibitors alone or in combination with established cytotoxic drugs in cancer chemotherapy.
    Grant S; Roberts JD
    Drug Resist Updat; 2003 Feb; 6(1):15-26. PubMed ID: 12654284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel direct and indirect cyclin-dependent kinase modulators for the prevention and treatment of human neoplasms.
    Senderowicz AM
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S61-73. PubMed ID: 12819936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel small molecule cyclin-dependent kinases modulators in human clinical trials.
    Senderowicz AM
    Cancer Biol Ther; 2003; 2(4 Suppl 1):S84-95. PubMed ID: 14508085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclin-dependent kinase inhibitors.
    Dai Y; Grant S
    Curr Opin Pharmacol; 2003 Aug; 3(4):362-70. PubMed ID: 12901944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small-molecule cyclin-dependent kinase modulators.
    Senderowicz AM
    Oncogene; 2003 Sep; 22(42):6609-20. PubMed ID: 14528286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclin-dependent kinase inhibitors as anticancer drugs.
    Krystof V; Uldrijan S
    Curr Drug Targets; 2010 Mar; 11(3):291-302. PubMed ID: 20210754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical and clinical development of cyclin-dependent kinase modulators.
    Senderowicz AM; Sausville EA
    J Natl Cancer Inst; 2000 Mar; 92(5):376-87. PubMed ID: 10699068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small molecule inhibitors targeting cyclin-dependent kinases as anticancer agents.
    Dai Y; Grant S
    Curr Oncol Rep; 2004 Mar; 6(2):123-30. PubMed ID: 14751090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclin-dependent kinase and protein kinase C inhibitors: a novel class of antineoplastic agents in clinical development.
    Kaubisch A; Schwartz GK
    Cancer J; 2000; 6(4):192-212. PubMed ID: 11038138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of cyclin-dependent kinase modulators as novel therapeutic approaches for hematological malignancies.
    Senderowicz AM
    Leukemia; 2001 Jan; 15(1):1-9. PubMed ID: 11243375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Flavopiridol, the first cyclin-dependent kinase inhibitor: recent advances in combination chemotherapy.
    Wang LM; Ren DM
    Mini Rev Med Chem; 2010 Oct; 10(11):1058-70. PubMed ID: 21047304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials.
    Senderowicz AM
    Invest New Drugs; 1999; 17(3):313-20. PubMed ID: 10665481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small molecule modulators of cyclin-dependent kinases for cancer therapy.
    Senderowicz AM
    Oncogene; 2000 Dec; 19(56):6600-6. PubMed ID: 11426645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclin-dependent kinase modulators: a novel class of cell cycle regulators for cancer therapy.
    Senderowicz AM
    Cancer Chemother Biol Response Modif; 2001; 19():165-88. PubMed ID: 11686013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclin-dependent kinases as new targets for the prevention and treatment of cancer.
    Senderowicz AM
    Hematol Oncol Clin North Am; 2002 Oct; 16(5):1229-53. PubMed ID: 12512390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early development of cyclin dependent kinase modulators.
    Roy KK; Sausville EA
    Curr Pharm Des; 2001 Nov; 7(16):1669-87. PubMed ID: 11562305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclin-dependent kinases as targets for cancer therapy.
    Senderowicz AM
    Cancer Chemother Biol Response Modif; 2002; 20():169-96. PubMed ID: 12703205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclin-dependent kinase modulators studied at the NCI: pre-clinical and clinical studies.
    Sausville EA
    Curr Med Chem Anticancer Agents; 2003 Jan; 3(1):47-56. PubMed ID: 12678914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CDK inhibitors in cancer therapy: what is next?
    Malumbres M; Pevarello P; Barbacid M; Bischoff JR
    Trends Pharmacol Sci; 2008 Jan; 29(1):16-21. PubMed ID: 18054800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conversion of drug-induced differentiation to apoptosis by pharmacologic cyclin-dependent kinase inhibitors.
    Grant S; Dent P
    Cell Cycle; 2002; 1(6):383-8. PubMed ID: 12548009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.